» Articles » PMID: 21541002

Physio-pathological Roles of Transglutaminase-catalyzed Reactions

Overview
Specialty Biochemistry
Date 2011 May 5
PMID 21541002
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Transglutaminases (TGs) are a large family of related and ubiquitous enzymes that catalyze post-translational modifications of proteins. The main activity of these enzymes is the cross-linking of a glutaminyl residue of a protein/peptide substrate to a lysyl residue of a protein/peptide co-substrate. In addition to lysyl residues, other second nucleophilic co-substrates may include monoamines or polyamines (to form mono- or bi-substituted /crosslinked adducts) or -OH groups (to form ester linkages). In the absence of co-substrates, the nucleophile may be water, resulting in the net deamidation of the glutaminyl residue. The TG enzymes are also capable of catalyzing other reactions important for cell viability. The distribution and the physiological roles of TG enzymes have been widely studied in numerous cell types and tissues and their roles in several diseases have begun to be identified. "Tissue" TG (TG2), a member of the TG family of enzymes, has definitely been shown to be involved in the molecular mechanisms responsible for a very widespread human pathology: i.e. celiac disease (CD). TG activity has also been hypothesized to be directly involved in the pathogenetic mechanisms responsible for several other human diseases, including neurodegenerative diseases, which are often associated with CD. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, supranuclear palsy, Huntington's disease and other recently identified polyglutamine diseases, are characterized, in part, by aberrant cerebral TG activity and by increased cross-linked proteins in affected brains. In this review, we discuss the physio-pathological role of TG-catalyzed reactions, with particular interest in the molecular mechanisms that could involve these enzymes in the physio-pathological processes responsible for human neurodegenerative diseases.

Citing Articles

Transglutaminase Type 2 regulates the Wnt/β-catenin pathway in vertebrates.

Rossin F, Costa R, Bordi M, DEletto M, Occhigrossi L, Farrace M Cell Death Dis. 2021; 12(3):249.

PMID: 33674551 PMC: 7935911. DOI: 10.1038/s41419-021-03485-2.


Characterisation of a novel cold-adapted calcium-activated transglutaminase: implications for medicine and food processing.

Alvarez R, Karki P, Langleite I, Bakksjo R, Eichacker L, Furnes C FEBS Open Bio. 2020; 10(4):495-506.

PMID: 32115900 PMC: 7137806. DOI: 10.1002/2211-5463.12826.


Candesartan Neuroprotection in Rat Primary Neurons Negatively Correlates with Aging and Senescence: a Transcriptomic Analysis.

Elkahloun A, Saavedra J Mol Neurobiol. 2019; 57(3):1656-1673.

PMID: 31811565 PMC: 7062590. DOI: 10.1007/s12035-019-01800-9.


Cellular Factor XIII, a Transglutaminase in Human Corneal Keratocytes.

Orosz Z, Bardos H, Shemirani A, Debreceni I, Lassila R, Riikonen A Int J Mol Sci. 2019; 20(23).

PMID: 31783511 PMC: 6928837. DOI: 10.3390/ijms20235963.


Immune-mediated Cerebellar Ataxias: Practical Guidelines and Therapeutic Challenges.

Mitoma H, Manto M, Hampe C Curr Neuropharmacol. 2018; 17(1):33-58.

PMID: 30221603 PMC: 6341499. DOI: 10.2174/1570159X16666180917105033.


References
1.
Junn E, Ronchetti R, Quezado M, Kim S, Mouradian M . Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 2003; 100(4):2047-52. PMC: 149956. DOI: 10.1073/pnas.0438021100. View

2.
Olaisen B, Gedde-Dahl Jr T, Teisberg P, Thorsby E, Siverts A, Jonassen R . A structural locus for coagulation factor XIIIA (F13A) is located distal to the HLA region on chromosome 6p in man. Am J Hum Genet. 1985; 37(1):215-20. PMC: 1684556. View

3.
Hartley D, Zhao C, Speier A, Woodard G, Li S, Li Z . Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation. J Biol Chem. 2008; 283(24):16790-800. PMC: 2423271. DOI: 10.1074/jbc.M802215200. View

4.
Onodera O, Oyake M, Takano H, Ikeuchi T, Igarashi S, Tsuji S . Molecular cloning of a full-length cDNA for dentatorubral-pallidoluysian atrophy and regional expressions of the expanded alleles in the CNS. Am J Hum Genet. 1995; 57(5):1050-60. PMC: 1801383. View

5.
Nanda N, Iismaa S, Owens W, Husain A, Mackay F, Graham R . Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem. 2001; 276(23):20673-8. DOI: 10.1074/jbc.M010846200. View